Collectively, our in vivo evidence establishes RPL11 as a pathogenic driver within renal cells, where its activity induces tubular epithelial apoptosis, recruits pro-inflammatory macrophages, and disrupts the local immune microenvironment, which provides a compelling rationale for the therapeutic targeting of si-RPL11 in AKI. This evidence concerns the gene RPL11 and acute kidney injury.